An interventional study of mCBT-AR in Avoidant/Restrictive Food Intake Disorder (ARFID), sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Avoidant Restrictive Food Intake Disorder with a site in United States — 7 open to participants now, 7 under way, none of them phase 3. Avoidant Restrictive Food Intake Disorder · United States.
Among the 23 studies in Avoidant Restrictive Food Intake Disorder with a site in United States, this one is the 6th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2026, is one of 17 with no phase, and was the 20th registered.
41 studies on the registry are indexed under Avoidant Restrictive Food Intake Disorder; 12 are open to participants now.
Browse Avoidant Restrictive Food Intake Disorder studies →7 of the 23 studies in Avoidant Restrictive Food Intake Disorder with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 10–18
University of North Carolina, Chapel Hill · Sites in United States, Australia, Mexico and 2 more countries
Ages 12–99 · Healthy volunteers
Brain Inflammation Collaborative · Sites in United States
Ages 2+ · Healthy volunteers
University of Louisville · Sites in United States
Ages 18+ · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Avoidant Restrictive Food Intake Disorder studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 5 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 38 across 28 interventional studies indexed under Avoidant Restrictive Food Intake Disorder.
Median enrollment 38 across the 18 interventional studies, 5,076 across the 5 observational. Of the 15 that completed or were terminated, 3 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 23 has an industry lead sponsor. The 10 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Massachusetts General Hospital has 5 studies filed under Avoidant Restrictive Food Intake Disorder — fewer than ten, so there is no comparison to draw.
2 of the studies in Avoidant Restrictive Food Intake Disorder with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05587127Massachusetts General HospitalExposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia | 2027-05 |
| NCT06594913University of North Carolina, Chapel HillEating Disorders Genetics Initiative 2 | 2027-09-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Avoidant Restrictive Food Intake Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Avoidant/restrictive food intake disorder (ARFID) is a serious and impairing eating disorder - occurring in up to 4% of adults - for which most individuals do not have access to treatment. The proposed study aims to develop and test a mobile app to scale delivery of cognitive-behavioral therapy for ARFID. Knowledge gained will contribute to the development of a clinically accessible, scalable, inexpensive treatment for ARFID, a highly impairing disorder for which there are significant barriers to care access.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
6. Medical instability requiring inpatient care according to the American Psychiatric Association 2023 treatment guidelines for eating disorders 7. Medical history of intellectual disability 8. Illiteracy
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: mCBT-AR
mCBT-AR is an 8-week virtual treatment for avoidant/restrictive food intake disorder delivered via mobile application
Pica, ARFID, and Rumination Disorder Interview - ARFID Questionnaire (PARDI-AR-Q)
The PARDI-AR-Q is a 32-item self-report measure based on the Pica, ARFID, and Rumination Disorder Interview that assesses ARFID diagnostic criteria and the presence and severity of each ARFID profile. Severity scores for each profile range from 0-6, with higher scores indicating greater severity.
Time frame: Change from baseline (assessed at study entry) to final session, which occurs an average of eight weeks after baseline (measured at weekly study treatment sessions)
Food Neophobia Scale (FNS)
The Food Neophobia Scale is a 6-item measure that measures reluctance to try new foods. Scores range from 7-42. Higher scores on the FNS are indicative of greater behavioral responses to novel foods.
Time frame: Change from baseline (assessed at study entry) to final session, which occurs an average of eight weeks after baseline (measured at weekly study treatment sessions)
Started Apr 2026 (actual). Primary completion is estimated for Apr 2030, 47 months after the start.
Of 16 interventional studies with no phase under Avoidant Restrictive Food Intake Disorder, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 43. This study's planned 47 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Avoidant Restrictive Food Intake Disorder →
Massachusetts General Hospital →